JP2020537528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537528A5 JP2020537528A5 JP2020521596A JP2020521596A JP2020537528A5 JP 2020537528 A5 JP2020537528 A5 JP 2020537528A5 JP 2020521596 A JP2020521596 A JP 2020521596A JP 2020521596 A JP2020521596 A JP 2020521596A JP 2020537528 A5 JP2020537528 A5 JP 2020537528A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hla
- sequence
- locus
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015050A JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
| EPPCT/EP2017/076798 | 2017-10-19 | ||
| EP2018053343 | 2018-02-09 | ||
| EPPCT/EP2018/053343 | 2018-02-09 | ||
| PCT/EP2018/055957 WO2019076486A1 (en) | 2017-10-19 | 2018-03-09 | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015050A Division JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537528A JP2020537528A (ja) | 2020-12-24 |
| JP2020537528A5 true JP2020537528A5 (enExample) | 2021-04-08 |
| JP7621795B2 JP7621795B2 (ja) | 2025-01-27 |
Family
ID=66173541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12209125B2 (enExample) |
| EP (2) | EP3684919A1 (enExample) |
| JP (2) | JP7621795B2 (enExample) |
| KR (2) | KR20250007705A (enExample) |
| CN (1) | CN111511903B (enExample) |
| AU (2) | AU2018353112B2 (enExample) |
| CA (1) | CA3084476A1 (enExample) |
| IL (1) | IL273828B2 (enExample) |
| MX (1) | MX2020004444A (enExample) |
| WO (2) | WO2019076486A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018189360A1 (en) * | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| WO2019076486A1 (en) | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| JP2022531185A (ja) | 2019-04-30 | 2022-07-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法 |
| MX2021013223A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos. |
| PH12021553254A1 (en) * | 2019-06-27 | 2022-09-19 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| EP4025224A1 (en) | 2019-09-05 | 2022-07-13 | CRISPR Therapeutics AG | Universal donor cells |
| JP7753197B2 (ja) * | 2019-09-05 | 2025-10-14 | クリスパー セラピューティクス アクチェンゲゼルシャフト | ユニバーサルドナー細胞 |
| EP4031654A4 (en) * | 2019-09-20 | 2023-11-22 | The University of North Carolina at Chapel Hill | MODIFIED T CELLS AND METHOD FOR PRODUCING THEREOF |
| IL294388A (en) | 2020-01-14 | 2022-08-01 | Synthekine Inc | Il2 orthologs and methods of use |
| AU2021288224A1 (en) * | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| WO2021263075A1 (en) * | 2020-06-26 | 2021-12-30 | St. Jude Children's Research Hospital, Inc. | Methods of generating an activation inducible expression system in immune cells |
| EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| WO2022020860A2 (en) * | 2020-07-24 | 2022-01-27 | Board Of Regents, The University Of Texas System | Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing |
| WO2022112596A1 (en) | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
| WO2022143783A1 (en) * | 2020-12-29 | 2022-07-07 | Edigene Therapeutics (Beijing) Inc. | Methods of identifying t-cell modulating genes |
| KR20230146007A (ko) | 2020-12-31 | 2023-10-18 | 크리스퍼 테라퓨틱스 아게 | 범용 공여자 세포 |
| KR20240007179A (ko) * | 2021-04-30 | 2024-01-16 | 셀렉티스 에스.에이. | 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포 |
| MX2023015153A (es) * | 2021-07-01 | 2024-04-16 | Ningbo T Maximum Biopharmaceuticals Co Ltd | Polipéptido de unión a antígeno que se dirige a b7h3 y aplicación del mismo. |
| WO2023016514A1 (zh) * | 2021-08-12 | 2023-02-16 | 苏州克睿基因生物科技有限公司 | 经修饰的细胞、其制备方法及应用 |
| WO2023212566A1 (en) * | 2022-04-25 | 2023-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing t cell exhaustion |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| AU2024259472A1 (en) * | 2023-04-20 | 2025-11-13 | Peter Maccallum Cancer Institute | Compositions and methods for immunotherapy - ii |
| WO2024258835A1 (en) * | 2023-06-16 | 2024-12-19 | The Trustees Of Columbia University In The City Of New York | Removal of endogenous tcr chains for enhanced tcr-based immunotherapies |
| TW202509218A (zh) * | 2023-07-12 | 2025-03-01 | 亨利傑克森軍方醫學基金會 | 用於抑制自然殺手細胞之組合物及方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
| CN106834320B (zh) | 2009-12-10 | 2021-05-25 | 明尼苏达大学董事会 | Tal效应子介导的dna修饰 |
| US20120189621A1 (en) * | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| EP2699593B2 (en) * | 2011-04-20 | 2020-11-04 | University of Washington Through Its Center for Commercialization | Beta-2 microglobulin-deficient cells |
| HUE064187T2 (hu) | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| US20150283233A1 (en) * | 2012-06-15 | 2015-10-08 | Gencia Corporation | Compositions and Methods for Enhancing Immune Responses |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| AU2014273490B2 (en) * | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
| EP3693384B1 (en) | 2014-03-11 | 2024-01-24 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
| CN107109368A (zh) * | 2014-10-07 | 2017-08-29 | 塞勒克提斯公司 | 用于调节car诱导的免疫细胞活性的方法 |
| BR112017018224A2 (pt) * | 2015-03-11 | 2018-04-17 | Cellectis | métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes |
| WO2016164492A2 (en) * | 2015-04-06 | 2016-10-13 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| AU2016261600B2 (en) | 2015-05-08 | 2021-09-23 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| IL257105B (en) * | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| US11091780B2 (en) * | 2015-09-18 | 2021-08-17 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
| CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| EP4012415A3 (en) | 2015-12-04 | 2022-12-07 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| TW201740958A (zh) * | 2016-01-15 | 2017-12-01 | 依圖比克斯公司 | 用於t細胞免疫療法之方法及組合物 |
| AU2017336094A1 (en) * | 2016-09-29 | 2019-04-18 | Immunitybio, Inc. | HLA class I-deficient NK-92 cells with decreased immunogenicity |
| CN106636090B (zh) | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| WO2019076486A1 (en) | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
-
2018
- 2018-03-09 WO PCT/EP2018/055957 patent/WO2019076486A1/en not_active Ceased
- 2018-03-09 IL IL273828A patent/IL273828B2/en unknown
- 2018-03-09 EP EP18719441.0A patent/EP3684919A1/en active Pending
- 2018-03-09 JP JP2020521596A patent/JP7621795B2/ja active Active
- 2018-03-09 KR KR1020247043433A patent/KR20250007705A/ko active Pending
- 2018-03-09 KR KR1020207014099A patent/KR20200075851A/ko not_active Ceased
- 2018-03-09 CA CA3084476A patent/CA3084476A1/en active Pending
- 2018-03-09 US US16/755,082 patent/US12209125B2/en active Active
- 2018-03-09 MX MX2020004444A patent/MX2020004444A/es unknown
- 2018-03-09 CN CN201880082153.1A patent/CN111511903B/zh active Active
- 2018-03-09 AU AU2018353112A patent/AU2018353112B2/en active Active
- 2018-04-16 US US16/755,093 patent/US12221478B2/en active Active
- 2018-04-16 AU AU2018351689A patent/AU2018351689B2/en active Active
- 2018-04-16 EP EP18722412.6A patent/EP3673049A1/en active Pending
- 2018-04-16 WO PCT/EP2018/059692 patent/WO2019076489A1/en not_active Ceased
-
2023
- 2023-02-03 JP JP2023015050A patent/JP2023055884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537528A5 (enExample) | ||
| JP2023055884A5 (enExample) | ||
| JP7590015B2 (ja) | 低抗原性細胞の製造方法 | |
| CN107630006B (zh) | 一种制备tcr与hla双基因敲除的t细胞的方法 | |
| AU2019261783B2 (en) | MND promoter chimeric antigen receptors | |
| US11141471B2 (en) | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells | |
| US20220170097A1 (en) | Car t cell transcriptional atlas | |
| JP2021534783A (ja) | キメラ抗原受容体発現細胞を作製する方法 | |
| CN110358736B (zh) | 一种修饰的k562细胞、其制备方法及nk细胞培养组合物 | |
| JP2019536447A5 (enExample) | ||
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| JP2020518256A5 (enExample) | ||
| JP2013538562A5 (enExample) | ||
| JP2017508457A (ja) | Ｔ細胞バランス遺伝子発現、組成物およびその使用方法 | |
| JPWO2021050601A5 (enExample) | ||
| JP2020528738A (ja) | ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ | |
| WO2019113132A1 (en) | Modified lymphocytes | |
| KR20230035048A (ko) | B 세포에서 b2m 로커스를 편집하는 방법 및 조성물 | |
| JP2023516538A (ja) | Ｕｃａｒｔ細胞を精製する方法及び応用 | |
| WO2022096664A1 (en) | Methods and compositions for eliminating engineered immune cells | |
| RU2020115282A (ru) | Целевая генная интеграция генов-ингибиторов nk для улучшенной иммунной клеточной терапии | |
| Cappabianca et al. | Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells | |
| US20240325441A1 (en) | Modified immune cell and use thereof | |
| AU2022271801A9 (en) | Nkg2c+ t cells and methods of use thereof | |
| CN114929878A (zh) | 用于改变基因序列的组合物及方法 |